C12N 2310/313
Phosphorodithioates
C12N2310/313 (Phosphorodithioates) appears on 173 US grants and 320 published applications in this corpus.
Search patents in C12N- Granted patents
- 173
- Published applications
- 320
- Assignees
- 123
- Inventors
- 572
- Latest grant
- 28 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 6 | 0 |
| 1998 | 1 | 0 |
| 1999 | 3 | 0 |
| 2000 | 2 | 0 |
| 2001 | 2 | 0 |
| 2002 | 2 | 1 |
| 2003 | 2 | 7 |
| 2004 | 1 | 3 |
| 2005 | 1 | 3 |
| 2006 | 2 | 3 |
| 2007 | 2 | 2 |
| 2008 | 0 | 2 |
| 2009 | 2 | 2 |
| 2010 | 1 | 0 |
| 2011 | 1 | 5 |
| 2012 | 5 | 14 |
| 2013 | 2 | 9 |
| 2014 | 3 | 8 |
| 2015 | 15 | 16 |
| 2016 | 8 | 12 |
| 2017 | 10 | 17 |
| 2018 | 11 | 13 |
| 2019 | 13 | 21 |
| 2020 | 11 | 19 |
| 2021 | 10 | 22 |
| 2022 | 12 | 22 |
| 2023 | 10 | 22 |
| 2024 | 14 | 38 |
| 2025 | 10 | 28 |
| 2026 | 10 | 31 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods of preparing oligonucleotide compositions using ultrafiltration/diafiltration28 Jul 2026US 12,692,495 B2Biogen MA Inc.
- Aptamer for IL-21 and use thereof7 Jul 2026US 12,674,170 B2Ribomic Inc.
- TREM compositions and uses thereof9 Jun 2026US 12,648,958 B2Flagship Pioneering Innovations VI, LLC
- Compounds and methods for reducing PLN expression12 May 2026US 12,624,358 B2Ionis Pharmaceuticals, Inc.
- Compositions for modulating C9ORF72 expression14 Apr 2026US 12,600,970 B2Ionis Pharmaceuticals, Inc.
- Treatment of gpam related diseases and disorders8 Oct 2026US 2026/0308594 A1Empirico Inc.
- Modified iscb nucleases, modified guide rnas, and uses thereof24 Sep 2026US 2026/0286324 A1Aera Therapeutics, Inc.
- Antisense oligonucleotides for the treatment of neurological disorders17 Sep 2026US 2026/0275339 A1Eli Lilly and Company
- Products and compositions10 Sep 2026US 2026/0265749 A1Silence Therapeutics GmbH
- RNAi Agents for Inhibiting Expression of Microtubule Associated Protein Tau (MAPT), Compositions Thereof, and Methods of Use27 Aug 2026US 2026/0248941 A1Arrowhead Pharmaceuticals, Inc.
Most cited
By later US patents
- Hybrid oligonucleotide phosphorothioates427US 5,652,355 AWorcester Foundation for Experimental Biology · 1997
- Immunostimulatory polynucleotide/immunomodulatory molecule conjugates162US 6,610,661 B1The Regents of the University of California · 2003
- Hybrid oligonucleotide phosphorothioates107US 6,346,614 B1Hybridon, Inc. · 2002
- Immunostimulatory polynucleotide/immunomodulatory molecule conjugates97US 7,208,478 B2The Regents of the University of California · 2007
- Means and methods for counteracting muscle disorders80US 9,243,245 B2Academisch Ziekenhuis Leiden · 2016